Enveda Raises $311M at $2B Valuation to Fast-Track AI-Discovered Nature Drugs
Enveda closed a $311 million Series E funding round at a $2 billion valuation, led by Catalio Capital Management with participation from Iconiq. The valuation doubled in just 12 months. The company uses AI to discover drugs from plants and microbes, with ongoing clinical trials for treatments targeting severe skin conditions and weight-loss maintenance after stopping GLP-1.
Executive Overview
Enveda, a pioneer in AI-driven natural product drug discovery, has closed a $311 million Series E funding round at a $2 billion valuation, led by Catalio Capital Management with participation from Iconiq and others. The valuation doubled in just 12 months, underscoring investor confidence in the company's approach to mining plants and microbes for novel therapeutics. The fresh capital will accelerate the advancement of multiple drug candidates into clinical trials, including treatments for severe skin conditions and weight-loss maintenance after GLP-1 discontinuation.
📊 Official Data & Technical Specifications Card
| Technical Axis | Confirmed Official Data |
|---|---|
| 💰 Pricing & Usage Cost | Not applicable (pharmaceutical company, not a software product). Funding: $311 million. Valuation: $2 billion. |
| 🌐 Platforms & Immediate Availability | Not applicable (biotech company). Headquarters in the United States. |
| ⚡ Performance & Speed Benchmarks | Accelerating drug discovery using AI. No specific benchmark numbers available. |
| 🛡️ Security & Breach Resistance | Not applicable (pharmaceutical field). |
| 🧠 Context Window (Memory) | Not applicable. |
| 🌍 Arabic Language & Regional Support | Not applicable (pharmaceutical company). No indication of services in the Arab region. |
Deep-Dive Features & Architecture
Founded in 2019 by Viswa Colluru, an early employee at Recursion Pharmaceuticals, Enveda was built on the premise that powerful drugs can be derived from plants and microbes rather than synthesized from scratch in the lab. The company leverages artificial intelligence and other technologies to accelerate the discovery of these new drugs. The new round, led by Catalio Capital Management with participation from Iconiq and others, brings the total funding raised to date and solidifies its position in the AI drug discovery space.
Enveda is part of a wave of companies pushing AI-discovered candidates into human clinical trials, although no FDA-approved AI-developed drugs exist yet. The company is currently testing several drugs in patients, including one targeting severe skin conditions and another designed to help maintain weight loss after discontinuing GLP-1 medications. This portfolio diversity reflects Enveda's strategy to explore multiple medical applications from natural sources.
Benchmark & Competitive Performance
Direct comparison numbers with other AI-driven natural product drug discovery companies are not available, but Enveda's $2 billion valuation places it among the prominent startups in this sector. For context, Snorkel AI, which operates in AI training data, reached a $3.5 billion valuation after tripling its value, indicating high investor appetite for specialized AI. However, the pharmaceutical sector remains more complex in terms of regulatory timelines and clinical trials.
Industry Impact & Enterprise Adoption
While Enveda is not a software company targeting Arab developers, its success in raising $311 million reflects growing confidence in AI applications in healthcare. Arab developers in medical AI can leverage this momentum to attract regional investments, especially with increasing interest in digital health in the region. Additionally, plant-derived drugs could open avenues for local research in traditional medicine supported by AI. However, the absence of direct Arabic support means current opportunities are concentrated in research and development rather than using a ready-made product.
Conclusion
This funding round marks a critical step for Enveda in proving that AI can accelerate drug discovery from nature. With a $2 billion valuation and $311 million in funding, the company has the resources to push more candidates into clinical trials. The next challenge is demonstrating efficacy and safety in human trials, which investors and the medical community will watch closely.
Media Source: TechCrunch AI | Fact Verification & Analysis: AI Tools Oasis
Frequently Asked Questions
Enveda raised $311 million in a Series E round at a $2 billion valuation, doubling its valuation from 12 months prior. The round was led by Catalio Capital Management with participation from Iconiq and others.
Enveda uses artificial intelligence and other technologies to discover new drugs from plants and microbes instead of synthesizing them from scratch in the lab, aiming to accelerate the drug development process.
Enveda is currently testing several drugs in patients, including one targeting severe skin conditions and another designed to help maintain weight loss after discontinuing GLP-1 medications.
Viswa Colluru, an early employee at Recursion Pharmaceuticals, founded Enveda in 2019 to accelerate natural drug discovery using AI.
No, AI has not yet produced any FDA-approved drugs, but Enveda is part of the wave pushing AI-discovered candidates into human clinical trials.
AI Tools Oasis Team
Bringing you the latest news and analysis in the world of Artificial Intelligence with accuracy and credibility. Follow us for all updates.
